<?xml version='1.0' encoding='UTF-8'?>
<!-- Created by Xince -->
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:pointofcarenano.com="http://pointofcarenano.com/20251031" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025">
  <link:schemaRef xlink:href="./PCNT_taxonomy_Q1_2024_2025.zip/PCNT_taxonomy_Q1_2024_2025/PCNT-20251231.xsd" xlink:type="simple"/>
  <xbrli:context id="c">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-11-01</xbrli:startDate>
      <xbrli:endDate>2023-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:ShareSubscriptionReceivedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-11-01</xbrli:startDate>
      <xbrli:endDate>2023-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-08-01</xbrli:startDate>
      <xbrli:endDate>2023-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:UnissuedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-11-01</xbrli:startDate>
      <xbrli:endDate>2023-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c4">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c5">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c6">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-11-01</xbrli:startDate>
      <xbrli:endDate>2023-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c7">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-11-01</xbrli:startDate>
      <xbrli:endDate>2023-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c8">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-11-01</xbrli:startDate>
      <xbrli:endDate>2023-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c9">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c10">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c11">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-02-01</xbrli:startDate>
      <xbrli:endDate>2023-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c12">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-02-01</xbrli:startDate>
      <xbrli:endDate>2023-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c13">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c14">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c15">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:ShareSubscriptionReceivedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-02-01</xbrli:startDate>
      <xbrli:endDate>2023-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c16">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-11-01</xbrli:startDate>
      <xbrli:endDate>2022-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c17">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-02-01</xbrli:startDate>
      <xbrli:endDate>2023-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c18">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:UnissuedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-02-01</xbrli:startDate>
      <xbrli:endDate>2023-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c19">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c20">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-02-01</xbrli:startDate>
      <xbrli:endDate>2023-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c21">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-02-01</xbrli:startDate>
      <xbrli:endDate>2023-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c22">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c23">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-08-01</xbrli:startDate>
      <xbrli:endDate>2022-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c24">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:ShareSubscriptionReceivedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c25">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:ShareSubscriptionReceivedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c26">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c27">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c28">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c29">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-02-01</xbrli:startDate>
      <xbrli:endDate>2023-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c32">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:ShareSubscriptionReceivedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c33">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c34">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:FormerAddressMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-08-01</xbrli:startDate>
      <xbrli:endDate>2023-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c35">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-05-01</xbrli:startDate>
      <xbrli:endDate>2023-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c36">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:UnissuedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c37">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c38">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-05-01</xbrli:startDate>
      <xbrli:endDate>2023-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c39">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c40">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c41">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-05-01</xbrli:startDate>
      <xbrli:endDate>2022-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c42">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:ShareSubscriptionReceivedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-05-01</xbrli:startDate>
      <xbrli:endDate>2023-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c43">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-11-01</xbrli:startDate>
      <xbrli:endDate>2023-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c44">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:UnissuedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-05-01</xbrli:startDate>
      <xbrli:endDate>2023-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c45">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-05-01</xbrli:startDate>
      <xbrli:endDate>2023-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c46">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-05-01</xbrli:startDate>
      <xbrli:endDate>2023-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c47">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c48">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-04-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c49">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c50">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:UnissuedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c51">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-08-01</xbrli:startDate>
      <xbrli:endDate>2023-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c52">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:UnissuedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c53">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-08-01</xbrli:startDate>
      <xbrli:endDate>2023-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c54">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:ShareSubscriptionReceivedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-08-01</xbrli:startDate>
      <xbrli:endDate>2023-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c55">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c56">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c57">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c58">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:UnissuedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-08-01</xbrli:startDate>
      <xbrli:endDate>2023-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c59">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c60">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-08-01</xbrli:startDate>
      <xbrli:endDate>2023-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c61">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-08-01</xbrli:startDate>
      <xbrli:endDate>2023-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c62">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c63">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:ShareSubscriptionReceivedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c64">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:UnissuedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-05-01</xbrli:startDate>
      <xbrli:endDate>2022-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c65">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:UnissuedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c66">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c67">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c68">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c69">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:ShareSubscriptionReceivedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c70">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-11-01</xbrli:startDate>
      <xbrli:endDate>2022-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c71">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-11-01</xbrli:startDate>
      <xbrli:endDate>2022-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c72">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:ShareSubscriptionReceivedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-11-01</xbrli:startDate>
      <xbrli:endDate>2022-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c73">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:UnissuedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-11-01</xbrli:startDate>
      <xbrli:endDate>2022-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c74">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-11-01</xbrli:startDate>
      <xbrli:endDate>2022-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c75">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-11-01</xbrli:startDate>
      <xbrli:endDate>2022-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c76">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c77">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:UnissuedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c78">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c79">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c80">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:ShareSubscriptionReceivedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c81">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:UnissuedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c82">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:UnissuedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c83">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c84">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-06-08</xbrli:startDate>
      <xbrli:endDate>2022-06-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c85">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c86">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c87">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-02-01</xbrli:startDate>
      <xbrli:endDate>2022-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c88">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-02-01</xbrli:startDate>
      <xbrli:endDate>2022-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c89">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:ShareSubscriptionReceivedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-02-01</xbrli:startDate>
      <xbrli:endDate>2022-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c90">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:UnissuedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-02-01</xbrli:startDate>
      <xbrli:endDate>2022-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c91">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-08-01</xbrli:startDate>
      <xbrli:endDate>2023-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c92">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-02-01</xbrli:startDate>
      <xbrli:endDate>2022-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c93">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-08-01</xbrli:startDate>
      <xbrli:endDate>2022-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c94">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-02-01</xbrli:startDate>
      <xbrli:endDate>2022-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c95">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c96">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2024-12-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c97">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-05-01</xbrli:startDate>
      <xbrli:endDate>2022-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c98">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:ShareSubscriptionReceivedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c99">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c100">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:UnissuedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c102">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c103">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-08-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c104">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-05-01</xbrli:startDate>
      <xbrli:endDate>2022-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c105">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-05-01</xbrli:startDate>
      <xbrli:endDate>2022-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c106">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:ShareSubscriptionReceivedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-05-01</xbrli:startDate>
      <xbrli:endDate>2022-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c107">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c108">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c109">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-10-02</xbrli:startDate>
      <xbrli:endDate>2024-10-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c110">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-05-01</xbrli:startDate>
      <xbrli:endDate>2022-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c111">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c112">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c113">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-10-02</xbrli:startDate>
      <xbrli:endDate>2024-10-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c114">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:ShareSubscriptionReceivedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-08-01</xbrli:startDate>
      <xbrli:endDate>2022-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c115">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c116">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c117">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:UnissuedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c118">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c119">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c120">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-04-10</xbrli:startDate>
      <xbrli:endDate>2022-04-10</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c121">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-08-01</xbrli:startDate>
      <xbrli:endDate>2023-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c122">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-11-05</xbrli:startDate>
      <xbrli:endDate>2024-11-05</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c123">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:ShareSubscriptionReceivedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c124">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-08-01</xbrli:startDate>
      <xbrli:endDate>2022-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c125">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-08-01</xbrli:startDate>
      <xbrli:endDate>2022-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c126">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c127">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c128">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2024-11-05</xbrli:startDate>
      <xbrli:endDate>2024-11-05</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c129">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:UnissuedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-08-01</xbrli:startDate>
      <xbrli:endDate>2022-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-08-01</xbrli:startDate>
      <xbrli:endDate>2022-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c131">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c132">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c133">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-08-01</xbrli:startDate>
      <xbrli:endDate>2022-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c134">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c135">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-05-01</xbrli:startDate>
      <xbrli:endDate>2022-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c136">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-05-01</xbrli:startDate>
      <xbrli:endDate>2023-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c137">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-02-01</xbrli:startDate>
      <xbrli:endDate>2022-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c138">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pointofcarenano.com:ShareSubscriptionReceivedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c139">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c140">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c141">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-11-01</xbrli:startDate>
      <xbrli:endDate>2022-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c142">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-11-01</xbrli:startDate>
      <xbrli:endDate>2023-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c143">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-01-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c144">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c145">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-05-01</xbrli:startDate>
      <xbrli:endDate>2023-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="c146">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001504239</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-02-01</xbrli:startDate>
      <xbrli:endDate>2022-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="usd1">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <us-gaap:NetIncomeLoss id="f" xsi:nil="true" contextRef="c" unitRef="usd"/>
  <us-gaap:NetIncomeLoss id="f1" xsi:nil="true" contextRef="c1" unitRef="usd"/>
  <us-gaap:IncreaseDecreaseInPrepaidExpense id="f2" decimals="0" contextRef="c2" unitRef="usd">-1440.0</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:NetIncomeLoss id="f3" xsi:nil="true" contextRef="c3" unitRef="usd"/>
  <pointofcarenano.com:UnissuedCommonStock id="f4" decimals="0" contextRef="c4" unitRef="usd">750000.0</pointofcarenano.com:UnissuedCommonStock>
  <us-gaap:SharesOutstanding id="f5" decimals="INF" contextRef="c5" unitRef="shares">1000.0</us-gaap:SharesOutstanding>
  <dei:EntityTaxIdentificationNumber id="f6" contextRef="c2">27-2830681</dei:EntityTaxIdentificationNumber>
  <us-gaap:NetIncomeLoss id="f7" xsi:nil="true" contextRef="c6" unitRef="usd"/>
  <us-gaap:NetIncomeLoss id="f8" xsi:nil="true" contextRef="c7" unitRef="usd"/>
  <us-gaap:PreferredStockSharesIssued id="f9" decimals="INF" contextRef="c4" unitRef="shares">1000.0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="f10" contextRef="c2">&lt;p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zVlMOTJMEgZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zhT9jvsD0U57"&gt;Financial
Instruments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments consist of cash and accounts payable and accrued liabilities. The carrying amounts of the financial instruments approximate
their fair values due to their relatively short-term nature of the underlying terms are consistent with market terms. As of the financial
statement date, the Company does not hold any derivate financial instruments. Financial assets and liabilities are measured upon first
recognition and reviewed at the financial statement date. Changes in fair value are recognized through profit and loss. Unless otherwise
noted, it is managements opinion that the Company is not exposed to significant interest or credit risks arising from these financial
instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:NetIncomeLoss id="f11" decimals="0" contextRef="c8" unitRef="usd">-13154.0</us-gaap:NetIncomeLoss>
  <us-gaap:StockholdersEquity id="f12" decimals="0" contextRef="c9" unitRef="usd">10248.0</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="f13" decimals="0" contextRef="c4" unitRef="usd">120252.0</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:StockholdersEquity id="f14" decimals="0" contextRef="c10" unitRef="usd">42.0</us-gaap:StockholdersEquity>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="f15" xsi:nil="true" contextRef="c11" unitRef="usd"/>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares id="f16" decimals="INF" contextRef="c12" unitRef="shares">520000.0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
  <us-gaap:StockholdersEquity id="f17" decimals="0" contextRef="c13" unitRef="usd">-80892.0</us-gaap:StockholdersEquity>
  <dei:EntityEmergingGrowthCompany id="f18" contextRef="c2">false</dei:EntityEmergingGrowthCompany>
  <us-gaap:PreferredStockSharesIssued id="f19" decimals="INF" contextRef="c14" unitRef="shares">1000.0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="f20" xsi:nil="true" contextRef="c15" unitRef="usd"/>
  <us-gaap:NetIncomeLoss id="f21" decimals="0" contextRef="c16" unitRef="usd">-13795.0</us-gaap:NetIncomeLoss>
  <us-gaap:PreferredStockSharesOutstanding id="f22" decimals="INF" contextRef="c14" unitRef="shares">1000.0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:NetIncomeLoss id="f23" decimals="0" contextRef="c17" unitRef="usd">-9773.0</us-gaap:NetIncomeLoss>
  <us-gaap:IncomeTaxPolicyTextBlock id="f24" contextRef="c2">&lt;p id="xdx_843_eus-gaap--IncomeTaxPolicyTextBlock_zjKbGqbCtFkg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zyNhb5Bzure5"&gt;Income
Taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes under FASB ASC Topic 740, Income Taxes (ASC Topic 740). Under ASC Topic 740, deferred
tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement
carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered
or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in
the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the
amount expected to be realized. As the Company has yet to produce positive cash flows from operations, no deferred tax asset or income
taxes have been recorded in the financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="f25" xsi:nil="true" contextRef="c18" unitRef="usd"/>
  <dei:DocumentPeriodEndDate id="f26" contextRef="c2">2023-10-31</dei:DocumentPeriodEndDate>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="f27" decimals="0" contextRef="c14" unitRef="usd">118865.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:ProfessionalFees id="f28" decimals="0" contextRef="c2" unitRef="usd">1767.0</us-gaap:ProfessionalFees>
  <us-gaap:StockholdersEquity id="f29" decimals="0" contextRef="c19" unitRef="usd">120192085.0</us-gaap:StockholdersEquity>
  <us-gaap:PreferredStockSharesOutstanding id="f30" decimals="INF" contextRef="c4" unitRef="shares">1000.0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="f31" xsi:nil="true" contextRef="c20" unitRef="usd"/>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="f32" xsi:nil="true" contextRef="c21" unitRef="usd"/>
  <us-gaap:StockholdersEquity id="f33" decimals="0" contextRef="c22" unitRef="usd">-52.0</us-gaap:StockholdersEquity>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="f34" xsi:nil="true" contextRef="c17" unitRef="usd"/>
  <us-gaap:IncreaseDecreaseInPrepaidExpense id="f35" decimals="0" contextRef="c23" unitRef="usd">-1750.0</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:StockholdersEquity id="f36" decimals="0" contextRef="c24" unitRef="usd">10000.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f37" decimals="0" contextRef="c25" unitRef="usd">20000.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f38" decimals="0" contextRef="c26" unitRef="usd">20021.0</us-gaap:StockholdersEquity>
  <us-gaap:NetIncomeLoss id="f39" xsi:nil="true" contextRef="c11" unitRef="usd"/>
  <us-gaap:StockholdersEquity id="f40" decimals="0" contextRef="c27" unitRef="usd">-52.0</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="f41" decimals="INF" contextRef="c28" unitRef="shares">1000.0</us-gaap:SharesOutstanding>
  <us-gaap:NetIncomeLoss id="f42" xsi:nil="true" contextRef="c29" unitRef="usd"/>
  <us-gaap:StockholdersEquity id="f43" decimals="0" contextRef="c30" unitRef="usd">-120928953.0</us-gaap:StockholdersEquity>
  <us-gaap:NetIncomeLoss id="f44" xsi:nil="true" contextRef="c15" unitRef="usd"/>
  <us-gaap:LiabilitiesAndStockholdersEquity id="f45" decimals="0" contextRef="c14" unitRef="usd">124643.0</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:SharesOutstanding id="f46" decimals="INF" contextRef="c22" unitRef="shares">-520000.0</us-gaap:SharesOutstanding>
  <us-gaap:NetIncomeLoss id="f47" xsi:nil="true" contextRef="c18" unitRef="usd"/>
  <us-gaap:PreferredStockValue id="f48" decimals="0" contextRef="c4" unitRef="usd">1.0</us-gaap:PreferredStockValue>
  <us-gaap:StockholdersEquity id="f49" decimals="0" contextRef="c31" unitRef="usd">-67097.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f50" decimals="0" contextRef="c32" unitRef="usd">20000.0</us-gaap:StockholdersEquity>
  <us-gaap:NetIncomeLoss id="f51" xsi:nil="true" contextRef="c12" unitRef="usd"/>
  <us-gaap:NetIncomeLoss id="f52" xsi:nil="true" contextRef="c20" unitRef="usd"/>
  <us-gaap:ProfessionalFees id="f53" decimals="0" contextRef="c23" unitRef="usd">3199.0</us-gaap:ProfessionalFees>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="f54" decimals="0" contextRef="c23" unitRef="usd">10000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:StockholdersEquity id="f55" xsi:nil="true" contextRef="c33" unitRef="usd"/>
  <us-gaap:SharesOutstanding id="f56" xsi:nil="true" contextRef="c33" unitRef="shares"/>
  <dei:EntityAddressAddressLine1 id="f57" contextRef="c34">109 Ambersweet Way</dei:EntityAddressAddressLine1>
  <pointofcarenano.com:ShareSubscriptionReceived id="f58" decimals="0" contextRef="c1" unitRef="usd">10000.0</pointofcarenano.com:ShareSubscriptionReceived>
  <us-gaap:NetIncomeLoss id="f59" xsi:nil="true" contextRef="c35" unitRef="usd"/>
  <us-gaap:CommonStockSharesOutstanding id="f60" decimals="INF" contextRef="c14" unitRef="shares">420621.0</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquity id="f61" decimals="0" contextRef="c5" unitRef="usd">1.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f62" decimals="0" contextRef="c36" unitRef="usd">750000.0</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="f63" decimals="INF" contextRef="c37" unitRef="shares">1000.0</us-gaap:SharesOutstanding>
  <us-gaap:NetIncomeLoss id="f64" xsi:nil="true" contextRef="c38" unitRef="usd"/>
  <us-gaap:Assets id="f65" decimals="0" contextRef="c4" unitRef="usd">120252.0</us-gaap:Assets>
  <us-gaap:SharesOutstanding id="f66" decimals="INF" contextRef="c39" unitRef="shares">420621.0</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="f67" decimals="INF" contextRef="c40" unitRef="shares">1000.0</us-gaap:SharesOutstanding>
  <us-gaap:StockRedeemedOrCalledDuringPeriodShares id="f68" decimals="INF" contextRef="c41" unitRef="shares">-520000.0</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
  <us-gaap:NetIncomeLoss id="f69" xsi:nil="true" contextRef="c42" unitRef="usd"/>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock id="f70" contextRef="c2">&lt;p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_ztDqV6XjQ2i2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zDY7PckTx4te"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows FASB Codification topic (ASC) 820, Fair Value Measurements and Disclosures, for all financial instruments
and non-financial instruments accounted for at fair value on a recurring basis. This new accounting standard establishes a single definition
of fair value and a framework for measuring fair value, sets out a fair value hierarchy to be used to classify the source of information
used in fair value measurement and expands disclosures about fair value measurements required under other accounting pronouncements.
It does not change existing guidance as to whether or not an instrument is carried at fair value. The Company defines fair value as the
price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at
fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based
risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer
restrictions and credit risk.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has adopted FASB ASC 825, Financial Instruments, which allows companies to choose to measure eligible financial instruments and
certain other items at fair value that are not required to be measured at fair value. The Company has not elected the fair value option
for any eligible financial instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
asset or liabilitys level within the fair value hierarchy is based on the lowest level of any input that is significant to the
fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment
in determining fair value of assets and liabilities, and Level 3 assets and liabilities involve greater judgment than Level 1 and Level
2 assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <pointofcarenano.com:ShareSubscriptionReceived id="f71" decimals="0" contextRef="c43" unitRef="usd">10000.0</pointofcarenano.com:ShareSubscriptionReceived>
  <pointofcarenano.com:License id="f72" decimals="0" contextRef="c14" unitRef="usd">125000.0</pointofcarenano.com:License>
  <us-gaap:NetIncomeLoss id="f73" decimals="0" contextRef="c43" unitRef="usd">-13154.0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="f74" xsi:nil="true" contextRef="c44" unitRef="usd"/>
  <dei:DocumentTransitionReport id="f75" contextRef="c2">false</dei:DocumentTransitionReport>
  <us-gaap:CashEquivalentsAtCarryingValue id="f76" decimals="0" contextRef="c14" unitRef="usd">498.0</us-gaap:CashEquivalentsAtCarryingValue>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="f77" decimals="0" contextRef="c12" unitRef="usd">52.0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
  <us-gaap:NetIncomeLoss id="f78" xsi:nil="true" contextRef="c45" unitRef="usd"/>
  <us-gaap:PreferredStockValue id="f79" decimals="0" contextRef="c14" unitRef="usd">1.0</us-gaap:PreferredStockValue>
  <us-gaap:CommonStockSharesIssued id="f80" decimals="INF" contextRef="c14" unitRef="shares">420621.0</us-gaap:CommonStockSharesIssued>
  <pointofcarenano.com:ShareSubscriptionsReceived id="f81" decimals="0" contextRef="c4" unitRef="usd">20000.0</pointofcarenano.com:ShareSubscriptionsReceived>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="f82" decimals="0" contextRef="c2" unitRef="usd">-75.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss id="f83" xsi:nil="true" contextRef="c46" unitRef="usd"/>
  <dei:EntitySmallBusiness id="f84" contextRef="c2">true</dei:EntitySmallBusiness>
  <us-gaap:StockholdersEquity id="f85" xsi:nil="true" contextRef="c47" unitRef="usd"/>
  <dei:EntityAddressCityOrTown id="f86" contextRef="c34">Davenport</dei:EntityAddressCityOrTown>
  <us-gaap:OperatingExpenses id="f87" decimals="0" contextRef="c23" unitRef="usd">28071.0</us-gaap:OperatingExpenses>
  <pointofcarenano.com:EarningsPerShareBasicAndDiluted1 id="f88" decimals="INF" contextRef="c2" unitRef="usd1">-0.01</pointofcarenano.com:EarningsPerShareBasicAndDiluted1>
  <us-gaap:SharesOutstanding id="f89" xsi:nil="true" contextRef="c47" unitRef="shares"/>
  <pointofcarenano.com:TreasuryStockShares1 id="f90" decimals="INF" contextRef="c48" unitRef="shares">520000.0</pointofcarenano.com:TreasuryStockShares1>
  <us-gaap:StockholdersEquity id="f91" decimals="0" contextRef="c49" unitRef="usd">120187430.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f92" decimals="0" contextRef="c50" unitRef="usd">750000.0</us-gaap:StockholdersEquity>
  <us-gaap:NetIncomeLoss id="f93" xsi:nil="true" contextRef="c51" unitRef="usd"/>
  <us-gaap:CommonStockSharesOutstanding id="f94" decimals="INF" contextRef="c4" unitRef="shares">420621.0</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:StockholdersEquity id="f95" decimals="0" contextRef="c52" unitRef="usd">750000.0</us-gaap:StockholdersEquity>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock id="f96" contextRef="c2">&lt;p id="xdx_84E_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zMsBb5MeHoM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zIX8CWcuwGu7"&gt;Comprehensive
Income (Loss)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted FASB ASC 220, Reporting Comprehensive Income, which establishes standards for the reporting and display of comprehensive
income and its components in the financial statements. Comprehensive income consists of net income and other gains and losses affecting
stockholders equity that are excluded from net income, such as unrealized gains and losses on investments available for sale,
foreign currency translation gains and losses and minimum pension liability. Since inception, the Company has not had any comprehensive
income / loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:NetIncomeLoss id="f97" xsi:nil="true" contextRef="c53" unitRef="usd"/>
  <dei:EntityAddressStateOrProvince id="f98" contextRef="c34">FL</dei:EntityAddressStateOrProvince>
  <us-gaap:Liabilities id="f99" decimals="0" contextRef="c4" unitRef="usd">143331.0</us-gaap:Liabilities>
  <pointofcarenano.com:NonCashTransactionsPolicyTextBlock id="f100" contextRef="c2">&lt;p id="xdx_844_ecustom--NonCashTransactionsPolicyTextBlock_zjLBcDsFJNd2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zsHKOo5zLc9a"&gt;Non-cash
transactions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows FASB ASC 845 then recording non-cash transactions. The value of the asset received should be based on the value of the
assets surrendered. However, where that value is difficult to determine, then the value could be based on the asset received, provided
it is more clearly evident than the value of the asset surrendered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

</pointofcarenano.com:NonCashTransactionsPolicyTextBlock>
  <us-gaap:NetIncomeLoss id="f101" xsi:nil="true" contextRef="c54" unitRef="usd"/>
  <us-gaap:Assets id="f102" decimals="0" contextRef="c14" unitRef="usd">124643.0</us-gaap:Assets>
  <us-gaap:StockholdersEquity id="f103" decimals="0" contextRef="c55" unitRef="usd">23175.0</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="f104" decimals="INF" contextRef="c56" unitRef="shares">1000.0</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="f105" decimals="INF" contextRef="c57" unitRef="shares">1000.0</us-gaap:SharesOutstanding>
  <us-gaap:PrepaidExpenseCurrent id="f106" decimals="0" contextRef="c4" unitRef="usd">3840.0</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:NetIncomeLoss id="f107" xsi:nil="true" contextRef="c58" unitRef="usd"/>
  <pointofcarenano.com:License id="f108" decimals="0" contextRef="c59" unitRef="usd">125000.0</pointofcarenano.com:License>
  <us-gaap:NetIncomeLoss id="f109" xsi:nil="true" contextRef="c60" unitRef="usd"/>
  <dei:EntityAddressPostalZipCode id="f110" contextRef="c34">33897</dei:EntityAddressPostalZipCode>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue id="f111" decimals="0" contextRef="c29" unitRef="usd">-52.0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
  <us-gaap:NetIncomeLoss id="f112" xsi:nil="true" contextRef="c61" unitRef="usd"/>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="f113" decimals="0" contextRef="c23" unitRef="usd">-7349.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:StockholdersEquity id="f114" xsi:nil="true" contextRef="c62" unitRef="usd"/>
  <us-gaap:SharesOutstanding id="f115" xsi:nil="true" contextRef="c62" unitRef="shares"/>
  <us-gaap:CommonStockParOrStatedValuePerShare id="f116" decimals="INF" contextRef="c4" unitRef="usd1">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued id="f117" decimals="INF" contextRef="c4" unitRef="shares">420621.0</us-gaap:CommonStockSharesIssued>
  <pointofcarenano.com:EarningsPerShareBasicAndDiluted1 id="f118" decimals="INF" contextRef="c23" unitRef="usd1">-0.03</pointofcarenano.com:EarningsPerShareBasicAndDiluted1>
  <us-gaap:StockholdersEquity id="f119" xsi:nil="true" contextRef="c63" unitRef="usd"/>
  <us-gaap:CommonStockParOrStatedValuePerShare id="f120" decimals="INF" contextRef="c14" unitRef="usd1">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <pointofcarenano.com:UnissuedCommonStocks id="f121" decimals="0" contextRef="c64" unitRef="usd">750000.0</pointofcarenano.com:UnissuedCommonStocks>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="f122" contextRef="c2">&lt;p id="xdx_800_eus-gaap--SignificantAccountingPoliciesTextBlock_zH5pfQbrrAF8" style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
    4&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 91%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82A_zlAGcLKmwvMb"&gt;ACCOUNTING
    POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States
of America, the more significant of which are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zamrXf5g0tjk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_z2SYVXd2CW6j"&gt;Consolidation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statement include the accounts of the Company and its wholly owned subsidiary Duo Sciences Inc. (DSI)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--UseOfEstimates_z73fYh6AvcCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zqiuOqQeiav1"&gt;Use
of Estimates&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent
assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period.
Changes in estimates are recognized in accordance with the accounting rules for the estimate, which is typically in the period when new
information becomes available to management. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zVlMOTJMEgZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zhT9jvsD0U57"&gt;Financial
Instruments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments consist of cash and accounts payable and accrued liabilities. The carrying amounts of the financial instruments approximate
their fair values due to their relatively short-term nature of the underlying terms are consistent with market terms. As of the financial
statement date, the Company does not hold any derivate financial instruments. Financial assets and liabilities are measured upon first
recognition and reviewed at the financial statement date. Changes in fair value are recognized through profit and loss. Unless otherwise
noted, it is managements opinion that the Company is not exposed to significant interest or credit risks arising from these financial
instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_ztDqV6XjQ2i2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zDY7PckTx4te"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows FASB Codification topic (ASC) 820, Fair Value Measurements and Disclosures, for all financial instruments
and non-financial instruments accounted for at fair value on a recurring basis. This new accounting standard establishes a single definition
of fair value and a framework for measuring fair value, sets out a fair value hierarchy to be used to classify the source of information
used in fair value measurement and expands disclosures about fair value measurements required under other accounting pronouncements.
It does not change existing guidance as to whether or not an instrument is carried at fair value. The Company defines fair value as the
price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at
fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based
risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer
restrictions and credit risk.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has adopted FASB ASC 825, Financial Instruments, which allows companies to choose to measure eligible financial instruments and
certain other items at fair value that are not required to be measured at fair value. The Company has not elected the fair value option
for any eligible financial instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
asset or liabilitys level within the fair value hierarchy is based on the lowest level of any input that is significant to the
fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment
in determining fair value of assets and liabilities, and Level 3 assets and liabilities involve greater judgment than Level 1 and Level
2 assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--RevenueRecognitionPolicyTextBlock_zyw5eR5ULukc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zakbhVcVhkrd"&gt;Revenue
Recognition&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
August 1, 2018, the Company adopted ASC, Topic 606, Revenue from Contracts with Customers, using the modified retrospective
transition method as permissible for all contracts not yet completed as of August 1, 2018. This standard applies to all contracts with
customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and
financial instruments.&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the
consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements
that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contracts)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the
transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance
obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration
it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--IncomeTaxPolicyTextBlock_zjKbGqbCtFkg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zyNhb5Bzure5"&gt;Income
Taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for income taxes under FASB ASC Topic 740, Income Taxes (ASC Topic 740). Under ASC Topic 740, deferred
tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement
carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered
or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in
the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the
amount expected to be realized. As the Company has yet to produce positive cash flows from operations, no deferred tax asset or income
taxes have been recorded in the financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zMsBb5MeHoM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zIX8CWcuwGu7"&gt;Comprehensive
Income (Loss)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted FASB ASC 220, Reporting Comprehensive Income, which establishes standards for the reporting and display of comprehensive
income and its components in the financial statements. Comprehensive income consists of net income and other gains and losses affecting
stockholders equity that are excluded from net income, such as unrealized gains and losses on investments available for sale,
foreign currency translation gains and losses and minimum pension liability. Since inception, the Company has not had any comprehensive
income / loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z2u8RHGnh6ee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zcNpf5EIbOG4"&gt;Net
Income (Loss) per Common Share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FASB
ASC 260, Earnings per share, requires dual presentation of basic and diluted earnings per share (EPS) with a reconciliation of the numerator
and denominator of the EPS computations. Basic earnings per share amounts are based on the weighted average shares of common stock outstanding.
If applicable, diluted earnings per share would assume the conversion, exercise or issuance of all potential common stock instruments
such as options, warrants and convertible securities, unless the effect is to reduce a loss or increase earnings per share. Diluted net
income (loss) per share on the potential exercise of the equity-based financial instruments is not presented where anti-dilutive. Accordingly,
although the diluted weighted average number of common stock outstanding is disclosed on the statements of operation, the calculated
net loss per share is the same for bother basic and diluted as both are based on the basic weighted average of common stock outstanding.
There were no adjustments required to net income for the period presented in the computation of diluted earnings per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zeVwIkRk0eY9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zUssr5rNsPz6"&gt;Segment
Reporting&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FASB
ASC 820, Segments Reporting, establishes standards for reporting information about operating segments on a basis consistent
with the Companys internal organization structure as well as information about geographical areas, business segments and major
customers in financial statements. The Company currently operates in one principal business segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zD6Uyn5KX2K5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zUQCrBPWuD15"&gt;Intangible
assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
asset are non-monetary identifiable assets, controlled by the Company that will produce future economic benefits, based on reasonable
and supportable assumptions about conditions that will exist over the life of the asset. An intangible asset that does not meet these
attributes will be recognized as an expense when it is incurred. Intangible assets that do, are capitalized and initially measure at
cost. Those with a determinable life will be amortized on a systematic basis over their future economic life. Those with an indefinite
useful life shall not be amortized until its useful life is determined to be longer than indefinite. An intangible asset subject to amortization
shall be periodically reviewed for impairment. A recoverability test will be performed and, if applicable, unscheduled amortization is
considered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
license agreements has been capitalized, recorded at cost and amortized over its estimated useful life of &lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxH_c20231031_zsopxcxWooL1" title="::XDX::P10Y"&gt;ten&lt;/span&gt; years. Amortization has
been determined based on a pro rata basis over the expected cash flows.&lt;/span&gt;&lt;/p&gt;





&lt;p id="xdx_844_ecustom--NonCashTransactionsPolicyTextBlock_zjLBcDsFJNd2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zsHKOo5zLc9a"&gt;Non-cash
transactions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows FASB ASC 845 then recording non-cash transactions. The value of the asset received should be based on the value of the
assets surrendered. However, where that value is difficult to determine, then the value could be based on the asset received, provided
it is more clearly evident than the value of the asset surrendered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--RelatedPartiesPolicyTextBlock_z337sBxTNOT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_z3DgOd8Q0M6c"&gt;Related
Parties&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted FASB ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSXbJmIct8Wh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zg49pYRfHApj"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopts new pronouncements relating to generally accepted accounting principles applicable to the Company as they are issued,
which may be in advance of their effective date. The Company does not expect the adoption of recently issued accounting pronouncements
to have a significant impact on the Companys results of operations, financial position, or cash flow.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States
of America, the more significant of which are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85D_z1OufP4dqZo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockholdersEquity id="f123" xsi:nil="true" contextRef="c65" unitRef="usd"/>
  <us-gaap:SharesOutstanding id="f124" decimals="INF" contextRef="c66" unitRef="shares">940621.0</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="f125" decimals="0" contextRef="c37" unitRef="usd">1.0</us-gaap:StockholdersEquity>
  <dei:DocumentType id="f126" contextRef="c2">10-Q/A</dei:DocumentType>
  <us-gaap:StockholdersEquity id="f127" xsi:nil="true" contextRef="c67" unitRef="usd"/>
  <us-gaap:Liabilities id="f128" decimals="0" contextRef="c14" unitRef="usd">141414.0</us-gaap:Liabilities>
  <us-gaap:StockholdersEquity id="f129" decimals="0" contextRef="c40" unitRef="usd">1.0</us-gaap:StockholdersEquity>
  <us-gaap:StockRedeemedOrCalledDuringPeriodValue id="f130" decimals="0" contextRef="c41" unitRef="usd">-52.0</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
  <us-gaap:SharesOutstanding id="f131" xsi:nil="true" contextRef="c67" unitRef="shares"/>
  <us-gaap:SharesOutstanding id="f132" decimals="INF" contextRef="c68" unitRef="shares">1000.0</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="f133" decimals="0" contextRef="c69" unitRef="usd">20000.0</us-gaap:StockholdersEquity>
  <us-gaap:NetIncomeLoss id="f134" xsi:nil="true" contextRef="c70" unitRef="usd"/>
  <us-gaap:NetIncomeLoss id="f135" xsi:nil="true" contextRef="c71" unitRef="usd"/>
  <us-gaap:IntangibleAssetsDisclosureTextBlock id="f136" contextRef="c2">&lt;p id="xdx_808_eus-gaap--IntangibleAssetsDisclosureTextBlock_zQPaSmaa10Je" style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
    7&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 91%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82C_zwEvtFRfe8ti"&gt;LICENSE
    PURCHASED and INTANGIBLE ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 11, 2022, the Company, through its wholly owned subsidiary DSI, acquired an exclusive license to distribute in the USA, Canada
and Mexico, certain intellectual property in animal nutrition and animal supplements from Cedoga Consulting, LLC. The Company receives
10% of all licensing fees due to Cedoga in exchange for 300,000 post reverse split shares of common stock of the Company. Under the terms
of the agreement, the Company will pay royalties from sub-licensing on the following basis:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;●&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 94%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;90%
    of net royalties for sale and initial payments up to $100,000,000 per calendar year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;●&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 94%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;95%
    of net royalties received for continuing sales above $100,000,000 per calendar year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;●&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 94%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;90%
    of any lump up-front payment sub-licensing fees.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;●&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 94%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Option
    to purchase 200,000 shares of the Companys common stock when net sales exceed $100,000,000.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; The
license value has been based on the expected discounted cash flows the license will generate to the Company over its estimated 10 year
life. The Companys common shares are very lightly traded and management determined that their market value are not reliable as
a determinant of value for this transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zd0UZ6R1iD9j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B9_zOQ1x3j4TMW" style="display: none"&gt;Schedule
of License Purchased&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_30F_134_zsy4ZuE7kOF8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%" summary="xdx: Disclosure - LICENSE PURCHASED and INTANGIBLE ASSETS (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt; &lt;/td&gt;&lt;td&gt; &lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230801__20231031_zrcEUKqH0kGc" style="white-space: nowrap; text-align: center"&gt;October 31,&lt;/td&gt;&lt;td&gt; &lt;/td&gt;&lt;td&gt; &lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220801__20230731_zSnfX3fvtAsl" style="white-space: nowrap; text-align: center"&gt;July 31,&lt;/td&gt;&lt;td&gt; &lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt; &lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt; &lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt; &lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--License_iS_z6ISpxYEkB83" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: justify"&gt;License&lt;/td&gt;&lt;td style="width: 3%"&gt; &lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;125,000&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt; &lt;/td&gt;&lt;td style="width: 3%"&gt; &lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;125,000&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt; &lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_zuvQ5vl6co44" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt; &lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt; &lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,011&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt; &lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt; &lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,135&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt; &lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iE_zMtoOwdndTJ" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Balance, end of year&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt; &lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;115,989&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt; &lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;118,865&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt; &lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zYm3L2qGnEeg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;
</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <us-gaap:AdditionalPaidInCapital id="f137" decimals="0" contextRef="c4" unitRef="usd">120192085.0</us-gaap:AdditionalPaidInCapital>
  <us-gaap:NetIncomeLoss id="f138" xsi:nil="true" contextRef="c72" unitRef="usd"/>
  <dei:EntityShellCompany id="f139" contextRef="c2">false</dei:EntityShellCompany>
  <pointofcarenano.com:SettlementContractsDisclosureTextBlock id="f140" contextRef="c2">&lt;p id="xdx_800_ecustom--SettlementContractsDisclosureTextBlock_z0GgtkOiapQk" style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
    6&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 91%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_820_zf5WUlKVXTUk"&gt;SETTLEMENT
    AGREEMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 15, 2021, the Company formed a wholly owned subsidiary, DRG Transfer Inc. (DRG) and transferred all Company debts
relating to the License Agreement business and the License Agreement to DRG to be split off to Dr. Guirguis in exchange for 520,000 shares
(26,000,000 shares pre reverse split) of our common stock held by Dr. Guirguis. This transaction closed on March 26, 2022 with Dr. Guirguis
giving up and transferring to DRG all the rights, title and interest in the 520,000 shares and DRG contributing all of the legacy business
debt and the License Agreement to DRG Transfer, Inc, a Nevada corporation, and transferring all of the outstanding capital stock in DRG
Transfer, Inc. to Dr. Guirguis Outstanding debts of the Company that were generated while Mr. Guirguis operated the Company, measured
as of April 15, 2021, consisted solely of unknown contingent liabilities (which could be identified or quantified at that time and which,
to date, have been non-material or nil.&lt;/span&gt;&lt;/p&gt;

</pointofcarenano.com:SettlementContractsDisclosureTextBlock>
  <us-gaap:NetIncomeLoss id="f141" xsi:nil="true" contextRef="c73" unitRef="usd"/>
  <us-gaap:DepreciationAndAmortization id="f142" decimals="0" contextRef="c2" unitRef="usd">2876.0</us-gaap:DepreciationAndAmortization>
  <us-gaap:NetIncomeLoss id="f143" xsi:nil="true" contextRef="c74" unitRef="usd"/>
  <dei:EntityAddressAddressLine1 id="f144" contextRef="c2">531     US HWY 22 East</dei:EntityAddressAddressLine1>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1 id="f145" decimals="0" contextRef="c2" unitRef="usd">9011.0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1>
  <us-gaap:NetIncomeLoss id="f146" xsi:nil="true" contextRef="c75" unitRef="usd"/>
  <us-gaap:StockholdersEquity id="f147" decimals="0" contextRef="c76" unitRef="usd">120192085.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f148" decimals="0" contextRef="c77" unitRef="usd">750000.0</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="f149" decimals="INF" contextRef="c78" unitRef="shares">1000.0</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="f150" decimals="INF" contextRef="c79" unitRef="shares">-520000.0</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="f151" xsi:nil="true" contextRef="c80" unitRef="usd"/>
  <us-gaap:StockholdersEquity id="f152" decimals="0" contextRef="c81" unitRef="usd">750000.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f153" xsi:nil="true" contextRef="c82" unitRef="usd"/>
  <us-gaap:StockholdersEquity id="f154" decimals="0" contextRef="c56" unitRef="usd">1.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f155" decimals="0" contextRef="c57" unitRef="usd">1.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f156" xsi:nil="true" contextRef="c83" unitRef="usd"/>
  <us-gaap:StockholdersEquityReverseStockSplit id="f157" contextRef="c84">On
June 8, 2022, the Company received approval from the Financial Industry Regulatory Authority to effect a 50:1 reverse split of our outstanding
common stock. The split was reflected in the public markets on June 9, 2022 and has been given retroactive disclosure in the financial
statements.</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:SharesOutstanding id="f158" xsi:nil="true" contextRef="c83" unitRef="shares"/>
  <dei:EntityCurrentReportingStatus id="f159" contextRef="c2">Yes</dei:EntityCurrentReportingStatus>
  <pointofcarenano.com:RelatedPartiesPolicyTextBlock id="f160" contextRef="c2">&lt;p id="xdx_84A_ecustom--RelatedPartiesPolicyTextBlock_z337sBxTNOT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_z3DgOd8Q0M6c"&gt;Related
Parties&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopted FASB ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

</pointofcarenano.com:RelatedPartiesPolicyTextBlock>
  <us-gaap:SharesOutstanding id="f161" decimals="INF" contextRef="c85" unitRef="shares">420621.0</us-gaap:SharesOutstanding>
  <us-gaap:EarningsPerSharePolicyTextBlock id="f162" contextRef="c2">&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_z2u8RHGnh6ee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zcNpf5EIbOG4"&gt;Net
Income (Loss) per Common Share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FASB
ASC 260, Earnings per share, requires dual presentation of basic and diluted earnings per share (EPS) with a reconciliation of the numerator
and denominator of the EPS computations. Basic earnings per share amounts are based on the weighted average shares of common stock outstanding.
If applicable, diluted earnings per share would assume the conversion, exercise or issuance of all potential common stock instruments
such as options, warrants and convertible securities, unless the effect is to reduce a loss or increase earnings per share. Diluted net
income (loss) per share on the potential exercise of the equity-based financial instruments is not presented where anti-dilutive. Accordingly,
although the diluted weighted average number of common stock outstanding is disclosed on the statements of operation, the calculated
net loss per share is the same for bother basic and diluted as both are based on the basic weighted average of common stock outstanding.
There were no adjustments required to net income for the period presented in the computation of diluted earnings per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:StockholdersEquity id="f163" decimals="0" contextRef="c86" unitRef="usd">120187430.0</us-gaap:StockholdersEquity>
  <us-gaap:NetIncomeLoss id="f164" xsi:nil="true" contextRef="c87" unitRef="usd"/>
  <dei:EntityFileNumber id="f165" contextRef="c2">000-56356</dei:EntityFileNumber>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="f166" decimals="0" contextRef="c2" unitRef="usd">-75.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:AdditionalPaidInCapital id="f167" decimals="0" contextRef="c14" unitRef="usd">120192085.0</us-gaap:AdditionalPaidInCapital>
  <us-gaap:NetIncomeLoss id="f168" xsi:nil="true" contextRef="c88" unitRef="usd"/>
  <dei:EntityAddressAddressLine2 id="f169" contextRef="c2">Suite     232</dei:EntityAddressAddressLine2>
  <us-gaap:NetIncomeLoss id="f170" xsi:nil="true" contextRef="c89" unitRef="usd"/>
  <us-gaap:DepreciationAndAmortization id="f171" decimals="0" contextRef="c23" unitRef="usd">1150.0</us-gaap:DepreciationAndAmortization>
  <us-gaap:NetIncomeLoss id="f172" xsi:nil="true" contextRef="c90" unitRef="usd"/>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1 id="f173" decimals="0" contextRef="c91" unitRef="usd">6135.0</us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1>
  <us-gaap:NetIncomeLoss id="f174" xsi:nil="true" contextRef="c92" unitRef="usd"/>
  <us-gaap:NetIncomeLoss id="f175" decimals="0" contextRef="c93" unitRef="usd">-28071.0</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="f176" decimals="0" contextRef="c23" unitRef="usd">-28071.0</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss id="f177" xsi:nil="true" contextRef="c94" unitRef="usd"/>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="f178" contextRef="c2">&lt;p id="xdx_842_eus-gaap--RevenueRecognitionPolicyTextBlock_zyw5eR5ULukc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zakbhVcVhkrd"&gt;Revenue
Recognition&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
August 1, 2018, the Company adopted ASC, Topic 606, Revenue from Contracts with Customers, using the modified retrospective
transition method as permissible for all contracts not yet completed as of August 1, 2018. This standard applies to all contracts with
customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and
financial instruments.&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the
consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements
that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contracts)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the
transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance
obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration
it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:StockholdersEquity id="f179" decimals="0" contextRef="c39" unitRef="usd">42.0</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="f180" decimals="INF" contextRef="c95" unitRef="shares">940621.0</us-gaap:SharesOutstanding>
  <dei:EntityCommonStockSharesOutstanding id="f181" decimals="INF" contextRef="c96" unitRef="shares">72790621.0</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:StockRedeemedOrCalledDuringPeriodValue id="f182" decimals="0" contextRef="c97" unitRef="usd">4655.0</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
  <us-gaap:StockholdersEquity id="f183" xsi:nil="true" contextRef="c98" unitRef="usd"/>
  <us-gaap:StockholdersEquity id="f184" decimals="0" contextRef="c68" unitRef="usd">1.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f185" decimals="0" contextRef="c99" unitRef="usd">120192085.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f186" xsi:nil="true" contextRef="c100" unitRef="usd"/>
  <us-gaap:StockholdersEquity id="f187" xsi:nil="true" contextRef="c101" unitRef="usd"/>
  <us-gaap:CommonStockValue id="f188" decimals="0" contextRef="c14" unitRef="usd">42.0</us-gaap:CommonStockValue>
  <us-gaap:StockholdersEquity id="f189" decimals="0" contextRef="c66" unitRef="usd">94.0</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding id="f190" decimals="INF" contextRef="c102" unitRef="shares">1000.0</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="f191" xsi:nil="true" contextRef="c101" unitRef="shares"/>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="f192" decimals="0" contextRef="c23" unitRef="usd">2651.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:PreferredStockSharesIssued id="f193" decimals="INF" contextRef="c103" unitRef="shares">1000.0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:StockRedeemedOrCalledDuringPeriodValue id="f194" xsi:nil="true" contextRef="c104" unitRef="usd"/>
  <dei:EntityAddressCityOrTown id="f195" contextRef="c2">Whitehouse     Station</dei:EntityAddressCityOrTown>
  <us-gaap:StockRedeemedOrCalledDuringPeriodValue id="f196" xsi:nil="true" contextRef="c105" unitRef="usd"/>
  <us-gaap:StockRedeemedOrCalledDuringPeriodValue id="f197" xsi:nil="true" contextRef="c106" unitRef="usd"/>
  <us-gaap:StockholdersEquity id="f198" decimals="0" contextRef="c107" unitRef="usd">-120900882.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f199" decimals="0" contextRef="c78" unitRef="usd">1.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f200" decimals="0" contextRef="c79" unitRef="usd">-52.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f201" decimals="0" contextRef="c108" unitRef="usd">-120254622.0</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f202" decimals="INF" contextRef="c109" unitRef="shares">1270000.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockRedeemedOrCalledDuringPeriodValue id="f203" xsi:nil="true" contextRef="c64" unitRef="usd"/>
  <pointofcarenano.com:ControlByPrincipalOwnersTextBlock id="f204" contextRef="c2">&lt;p id="xdx_801_ecustom--ControlByPrincipalOwnersTextBlock_zivwq3BBuFW4" style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
    2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 91%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_826_zqzAgOwGgLel"&gt;CONTROL
    BY PRINCIPAL OWNERS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
sole director and executive officer owns, directly, beneficially and in the aggregate, the majority of the voting power of the outstanding
capital stock of the Company. Accordingly, the sole director and executive officer has the ability to control the approval of most corporate
actions, including approving significant expenses, increasing the authorized capital and the dissolution, merger, or sale of the Companys
assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;
</pointofcarenano.com:ControlByPrincipalOwnersTextBlock>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="f205" decimals="0" contextRef="c4" unitRef="usd">-120985207.0</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockRedeemedOrCalledDuringPeriodValue id="f206" xsi:nil="true" contextRef="c110" unitRef="usd"/>
  <us-gaap:OperatingExpenses id="f207" decimals="0" contextRef="c2" unitRef="usd">6308.0</us-gaap:OperatingExpenses>
  <us-gaap:PrepaidExpenseCurrent id="f208" decimals="0" contextRef="c14" unitRef="usd">5280.0</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:SharesOutstanding id="f209" decimals="INF" contextRef="c111" unitRef="shares">940621.0</us-gaap:SharesOutstanding>
  <pointofcarenano.com:UnissuedCommonStocks id="f210" xsi:nil="true" contextRef="c104" unitRef="usd"/>
  <dei:EntityRegistrantName id="f211" contextRef="c2">POINT OF CARE NANO-TECHNOLOGY, INC.</dei:EntityRegistrantName>
  <us-gaap:StockholdersEquity id="f212" decimals="0" contextRef="c112" unitRef="usd">120192085.0</us-gaap:StockholdersEquity>
  <us-gaap:NetIncomeLoss id="f213" decimals="0" contextRef="c110" unitRef="usd">-626628.0</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f214" decimals="0" contextRef="c113" unitRef="usd">30000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <pointofcarenano.com:UnissuedCommonStocks id="f215" xsi:nil="true" contextRef="c105" unitRef="usd"/>
  <dei:EntityInteractiveDataCurrent id="f216" contextRef="c2">Yes</dei:EntityInteractiveDataCurrent>
  <pointofcarenano.com:UnissuedCommonStock id="f217" decimals="0" contextRef="c14" unitRef="usd">750000.0</pointofcarenano.com:UnissuedCommonStock>
  <pointofcarenano.com:UnissuedCommonStocks id="f218" xsi:nil="true" contextRef="c106" unitRef="usd"/>
  <dei:EntityAddressStateOrProvince id="f219" contextRef="c2">NJ</dei:EntityAddressStateOrProvince>
  <pointofcarenano.com:UnissuedCommonStocks id="f220" xsi:nil="true" contextRef="c41" unitRef="usd"/>
  <pointofcarenano.com:ShareSubscriptionReceived id="f221" decimals="0" contextRef="c114" unitRef="usd">10000.0</pointofcarenano.com:ShareSubscriptionReceived>
  <us-gaap:ConsolidationPolicyTextBlock id="f222" contextRef="c2">&lt;p id="xdx_846_eus-gaap--ConsolidationPolicyTextBlock_zamrXf5g0tjk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_z2SYVXd2CW6j"&gt;Consolidation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying consolidated financial statement include the accounts of the Company and its wholly owned subsidiary Duo Sciences Inc. (DSI)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
  <pointofcarenano.com:WeightedAverageNumberOfShareOutstandingBasicAndDiluted1 id="f223" decimals="INF" contextRef="c2" unitRef="shares">751142.0</pointofcarenano.com:WeightedAverageNumberOfShareOutstandingBasicAndDiluted1>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares id="f224" decimals="INF" contextRef="c29" unitRef="shares">-520000.0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
  <pointofcarenano.com:UnissuedCommonStocks id="f225" xsi:nil="true" contextRef="c97" unitRef="usd"/>
  <pointofcarenano.com:UnissuedCommonStocks id="f226" xsi:nil="true" contextRef="c110" unitRef="usd"/>
  <us-gaap:CommonStockSharesAuthorized id="f227" decimals="INF" contextRef="c14" unitRef="shares">100000000.0</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="f228" contextRef="c2">&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zSXbJmIct8Wh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zg49pYRfHApj"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company adopts new pronouncements relating to generally accepted accounting principles applicable to the Company as they are issued,
which may be in advance of their effective date. The Company does not expect the adoption of recently issued accounting pronouncements
to have a significant impact on the Companys results of operations, financial position, or cash flow.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States
of America, the more significant of which are as follows:&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock id="f229" contextRef="c2">&lt;p id="xdx_842_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zeVwIkRk0eY9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zUssr5rNsPz6"&gt;Segment
Reporting&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FASB
ASC 820, Segments Reporting, establishes standards for reporting information about operating segments on a basis consistent
with the Companys internal organization structure as well as information about geographical areas, business segments and major
customers in financial statements. The Company currently operates in one principal business segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:NetIncomeLoss id="f230" xsi:nil="true" contextRef="c104" unitRef="usd"/>
  <us-gaap:StockholdersEquity id="f231" decimals="0" contextRef="c115" unitRef="usd">120187430.0</us-gaap:StockholdersEquity>
  <pointofcarenano.com:ShareSubscriptionReceived id="f232" decimals="0" contextRef="c23" unitRef="usd">10000.0</pointofcarenano.com:ShareSubscriptionReceived>
  <us-gaap:NetIncomeLoss id="f233" decimals="0" contextRef="c23" unitRef="usd">-28071.0</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="f234" xsi:nil="true" contextRef="c105" unitRef="usd"/>
  <pointofcarenano.com:ShareSubscriptionsReceived id="f235" decimals="0" contextRef="c14" unitRef="usd">20000.0</pointofcarenano.com:ShareSubscriptionsReceived>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="f236" decimals="0" contextRef="c14" unitRef="usd">498.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="f237" decimals="0" contextRef="c14" unitRef="usd">-120978899.0</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:NetIncomeLoss id="f238" xsi:nil="true" contextRef="c106" unitRef="usd"/>
  <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock id="f239" contextRef="c2">&lt;p id="xdx_80B_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z8e1r3iq2We9" style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
    1&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 91%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82B_zdZIgetkVZul"&gt;COMPANY
    AND BACKGROUND&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Point
of Care Nano-Technology, Inc. (the Company) was incorporated under the laws of the State of Nevada on June 10, 2010, under
the name of Alternative Energy and Environmental Solutions, Inc. On August 28, 2014, the Company filed an amendment to
its Articles of Incorporation changing the name of the Company to Unique Growing Solutions, Inc. On March 31, 2015, the
Company filed an amendment to its Articles of Incorporation changing the name of the Company to Point of Care Nano-Technology,
Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 26, 2015, the Companys business model was related to using its license, under a certain license agreement (the License
Agreement) from Lamina Equities Corporation, to first develop and then manufacture saliva-based medical diagnosis products. The
Company was not successful and discontinued the majority of its operations by July 31, 2016. Beginning from August 2016, the Companys
plan, which it has since discontinued, was to provide business services and financing to emerging growth entities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 15, 2021, the Company accepted the resignations of Dr. Guirguis and Mr. El-Salhy, received a mutual release from both, and appointed
Mr. Nicholas DeVito to be Director, Chief Executive Officer and Chief Financial Officer. In addition, for his services to the Company,
Mr. DeVito was awarded 1,000 shares of Class A Preferred Stock that grants him 80% voting rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Also
on April 15, 2021 the Company agreed to form a subsidiary and transfer all debts and the License Agreement back to Dr. Guirguis in exchange
for 520,000 shares of Common Stock. On August 21, 2021, the Company formed the wholly owned subsidiary, DRG Transfer, Inc. This transaction
closed on March 26, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; On
July 2, 2021, the Company incorporated a wholly owned subsidiary, Duo Sciences, Inc. (DSI).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 11, 2022, the Company, through DSI, acquired an exclusive license to distribute certain intellectual property in animal nutrition
and animal supplements from Cedoga Consulting, LLC (Cedoga). On April 19, 2022, DSI signed an exclusive sales and promotion
agreement with Lucy Pet Products Inc. (Lucy) pursuant to which Lucy will manufacture, market and distribute pet products
from the Cedoga intellectual property.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Companys principal executive office location and mailing address is 531 US HWY 22 EAST, Suite 232, Whitehouse Station, NJ 08889.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
financial statements have been prepared in accordance with generally accepted principles applicable to a going concern, which assumes
that the Company will be able to meet its obligations and continue its operations for its next twelve months. Realization values may
be substantially different from carrying values as shown and these financial statements do not give effect to adjustments that would
be necessary to the carrying values and classifications of assets and liabilities should the Company be unable to continue as a going
concern. At October 31, 2023 the Company had not yet achieved profitable operations and had accumulated losses of $&lt;span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20231031_zC1QqKyf1Z47"&gt;120,985,207&lt;/span&gt; since
its inception, all of which casts substantial doubt about the Companys ability to continue as a going concern. The Companys
ability to continue as a going concern is dependent upon its ability to generate future profitable operations and/or to obtain the necessary
financing to meet its obligations and repay its liabilities arising from normal business operations when they come due.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;
</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
  <us-gaap:SharesOutstanding id="f240" decimals="INF" contextRef="c116" unitRef="shares">940621.0</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="f241" decimals="0" contextRef="c117" unitRef="usd">750000.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f242" decimals="0" contextRef="c118" unitRef="usd">120192085.0</us-gaap:StockholdersEquity>
  <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock id="f243" contextRef="c2">&lt;p id="xdx_895_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_zd0UZ6R1iD9j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B9_zOQ1x3j4TMW" style="display: none"&gt;Schedule
of License Purchased&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_30F_134_zsy4ZuE7kOF8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%" summary="xdx: Disclosure - LICENSE PURCHASED and INTANGIBLE ASSETS (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt; &lt;/td&gt;&lt;td&gt; &lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230801__20231031_zrcEUKqH0kGc" style="white-space: nowrap; text-align: center"&gt;October 31,&lt;/td&gt;&lt;td&gt; &lt;/td&gt;&lt;td&gt; &lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20220801__20230731_zSnfX3fvtAsl" style="white-space: nowrap; text-align: center"&gt;July 31,&lt;/td&gt;&lt;td&gt; &lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt; &lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt; &lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt; &lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--License_iS_z6ISpxYEkB83" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: justify"&gt;License&lt;/td&gt;&lt;td style="width: 3%"&gt; &lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;125,000&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt; &lt;/td&gt;&lt;td style="width: 3%"&gt; &lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;125,000&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt; &lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_zuvQ5vl6co44" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt; &lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt; &lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,011&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt; &lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt; &lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,135&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt; &lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iE_zMtoOwdndTJ" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Balance, end of year&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt; &lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;115,989&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt; &lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt; &lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;118,865&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1pt; text-align: left"&gt; &lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
  <us-gaap:SharesOutstanding id="f244" decimals="INF" contextRef="c10" unitRef="shares">420621.0</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="f245" decimals="0" contextRef="c119" unitRef="usd">-120985207.0</us-gaap:StockholdersEquity>
  <us-gaap:NetIncomeLoss id="f246" xsi:nil="true" contextRef="c64" unitRef="usd"/>
  <pointofcarenano.com:LicenseFeeToBePaidInCommonShares id="f247" decimals="0" contextRef="c120" unitRef="usd">750000.0</pointofcarenano.com:LicenseFeeToBePaidInCommonShares>
  <dei:EntityAddressPostalZipCode id="f248" contextRef="c2">08889</dei:EntityAddressPostalZipCode>
  <us-gaap:NetIncomeLoss id="f249" decimals="0" contextRef="c121" unitRef="usd">-6308.0</us-gaap:NetIncomeLoss>
  <us-gaap:SubsequentEventsTextBlock id="f250" contextRef="c2">&lt;p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_zRCoTUEg2t4i" style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
    9&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 91%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_826_z3UMpx9aZDNl"&gt;SUBSEQUENT
    EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 20, 2024, Point of Care Nano-Technology, Inc. (the Company) entered into an asset purchase agreement (the Agreement)
with Point of Care Nano-Technology, LLC (Point) pursuant to which it agreed to acquire (the Acquisition)
substantially all of the assets of Point (the Assets), consisting primarily of proprietary information and know-how for
the developing and commercialization of kits to diagnose illnesses through the testing of human saliva, referred to as the EZ
Saliva test kits, and cash in the amount of $101,400.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
exchange for the Assets, the Company issued to Point and/or its designees 66,000,000 restricted shares of common stock (the Consideration
Shares).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon
the closing of the Acquisition, which effected a change of control of the Company, Dr. Raouf Guirguis, the controlling member of Point,
became a director of the Company and Chief Scientific Officer. Dr. Guirguis also acquired, directly and indirectly, 34,647,800   of
the Consideration Shares, or approximately 47.6% of the shares of common stock outstanding after completion of the Acquisition. Mr. Nathan
Keele, an associate of Dr. Guirguis and responsible for marketing efforts at Point, also was appointed to the board of directors of the
Company. Mr. Keele will continue his marketing efforts at the Company. Mr. Keele acquired 18,903,200 of the Consideration Shares, or
approximately 26.5% of the shares of common stock outstanding after completion of the Acquisition.&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nicholas
DeVito, the controlling stockholder of the Company prior to the Acquisition through the 1,000 shares of super-majority class A preferred
stock (the Preferred Stock) of the Company that he held and through which he exercised eighty percent (80%) voting control
over the Company, surrendered to the Company for cancellation the Preferred Stock and received, in exchange, 5,000,000 shares of common
stock. Mr. DeVito will retain his positions as Chief Executive Officer, Chief Financial Officer, Treasurer and Secretary of the Company
as well as his status as a member of board of directors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
shares of Company common stock being issued in connection with the Acquisition (as described above) were issued in accordance with a
private placement exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, and are considered restricted
securities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the Acquisition, the Company entered into a license agreement (the License Agreement) with Zeus Diagnostics,
LLC (Zeus), a Delaware limited liability company controlled by Dr. Guirguis, pursuant to which the Company acquired an
exclusive, in perpetuity, license, with a right to sublicense, in the Territory (Canada, the United States and Mexico) to the Zeus
Know-How which consists of all information related to the manufacture and commercialization of saliva tests derived from patents
owned by Zeus. The Company paid Zeus a one-time, non-refundable up-front cash fee of $35,000 (which is creditable against other payments
due) and will pay Zeus a royalty on Net Sales (as defined in the License Agreement) of Seven and One-Half Percent (7.5%)
during each calendar quarter.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
the closing of the Acquisition, business will focus on the EZ Saliva product commercialization activity previously carried on by Point.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 2, 2024 the Company issued &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241002__20241002__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhLMPbkxHq56"&gt;1,270,000&lt;/span&gt; shares of common stock to three investors and raised $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241002__20241002__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPREFGi1wAsd"&gt;30,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 5, 2024, the Company issued &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20241105__20241105__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNFRjE6T5SUa"&gt;100,000&lt;/span&gt; shares of common stock to one investor and raised $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20241105__20241105__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zm2Br2OYkqrc"&gt;50,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:NetIncomeLoss id="f251" xsi:nil="true" contextRef="c41" unitRef="usd"/>
  <pointofcarenano.com:ConsultingExpense id="f252" decimals="0" contextRef="c23" unitRef="usd">20000.0</pointofcarenano.com:ConsultingExpense>
  <us-gaap:StockholdersEquity id="f253" decimals="0" contextRef="c102" unitRef="usd">1.0</us-gaap:StockholdersEquity>
  <us-gaap:NetIncomeLoss id="f254" xsi:nil="true" contextRef="c97" unitRef="usd"/>
  <us-gaap:CommonStockSharesAuthorized id="f255" decimals="INF" contextRef="c4" unitRef="shares">100000000.0</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="f256" decimals="INF" contextRef="c122" unitRef="shares">100000.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockholdersEquity id="f257" xsi:nil="true" contextRef="c123" unitRef="usd"/>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="f258" decimals="0" contextRef="c55" unitRef="usd">5849.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <pointofcarenano.com:WeightedAverageNumberOfShareOutstandingBasicAndDiluted1 id="f259" decimals="INF" contextRef="c23" unitRef="shares">940621.0</pointofcarenano.com:WeightedAverageNumberOfShareOutstandingBasicAndDiluted1>
  <pointofcarenano.com:ShareSubscriptionReceived id="f260" xsi:nil="true" contextRef="c124" unitRef="usd"/>
  <pointofcarenano.com:ShareSubscriptionReceived id="f261" xsi:nil="true" contextRef="c125" unitRef="usd"/>
  <us-gaap:StockholdersEquity id="f262" decimals="0" contextRef="c59" unitRef="usd">41246.0</us-gaap:StockholdersEquity>
  <us-gaap:AssetsCurrent id="f263" decimals="0" contextRef="c4" unitRef="usd">4263.0</us-gaap:AssetsCurrent>
  <us-gaap:SharesOutstanding id="f264" decimals="INF" contextRef="c27" unitRef="shares">-520000.0</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="f265" decimals="INF" contextRef="c126" unitRef="shares">940621.0</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="f266" decimals="0" contextRef="c127" unitRef="usd">120192085.0</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="f267" decimals="0" contextRef="c128" unitRef="usd">50000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <pointofcarenano.com:ShareSubscriptionReceived id="f268" xsi:nil="true" contextRef="c129" unitRef="usd"/>
  <pointofcarenano.com:ShareSubscriptionReceived id="f269" xsi:nil="true" contextRef="c130" unitRef="usd"/>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="f270" decimals="0" contextRef="c59" unitRef="usd">3198.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity id="f271" decimals="0" contextRef="c111" unitRef="usd">94.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f272" decimals="0" contextRef="c131" unitRef="usd">94.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f273" decimals="0" contextRef="c132" unitRef="usd">-120274254.0</us-gaap:StockholdersEquity>
  <pointofcarenano.com:ShareSubscriptionReceived id="f274" xsi:nil="true" contextRef="c133" unitRef="usd"/>
  <us-gaap:StockholdersEquity id="f275" decimals="0" contextRef="c134" unitRef="usd">-120978899.0</us-gaap:StockholdersEquity>
  <us-gaap:NetIncomeLoss id="f276" decimals="0" contextRef="c135" unitRef="usd">-626628.0</us-gaap:NetIncomeLoss>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="f277" decimals="0" contextRef="c2" unitRef="usd">1917.0</us-gaap:IncreaseDecreaseInAccountsPayable>
  <pointofcarenano.com:ExclusiveSalesSubLicensingAgreementTextBlock id="f278" contextRef="c2">&lt;p id="xdx_807_ecustom--ExclusiveSalesSubLicensingAgreementTextBlock_zbUUfQlhQCj5" style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
    8&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 91%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82E_zyBZC95Ci9se"&gt;EXCLUSIVE
    SALES  SUB-LICENSING AGREEMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 19, 2022, DSI signed an exclusive sales and promotion sub-licensing agreement with Lucy Pet Products Inc. (Lucy)
pursuant to which Lucy will manufacture, market and distribute pet products derived from the Cedoga intellectual property. The terms
of the sub-licensing agreement are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 4%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;●&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 72%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lucy
    will pay the Company a one-time sub-license fee of $100,000 on execution of the sub-licensing agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;●&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lucy
    will pay the Company royalties of 5% of Net Revenue, calculated and payable quarterly. Net Revenue is defined as total revenue less
    direct cost of materials, manufacturing, packaging and delivery expenses and less excise, sales or similar taxes.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;
</pointofcarenano.com:ExclusiveSalesSubLicensingAgreementTextBlock>
  <us-gaap:CashEquivalentsAtCarryingValue id="f279" decimals="0" contextRef="c4" unitRef="usd">423.0</us-gaap:CashEquivalentsAtCarryingValue>
  <us-gaap:NetIncomeLoss id="f280" decimals="0" contextRef="c136" unitRef="usd">-27019.0</us-gaap:NetIncomeLoss>
  <pointofcarenano.com:ShareSubscriptionReceived id="f281" xsi:nil="true" contextRef="c93" unitRef="usd"/>
  <us-gaap:NetIncomeLoss id="f282" decimals="0" contextRef="c137" unitRef="usd">-5837.0</us-gaap:NetIncomeLoss>
  <us-gaap:StockholdersEquity id="f283" decimals="0" contextRef="c85" unitRef="usd">42.0</us-gaap:StockholdersEquity>
  <us-gaap:NetIncomeLoss id="f284" xsi:nil="true" contextRef="c124" unitRef="usd"/>
  <us-gaap:NetIncomeLoss id="f285" xsi:nil="true" contextRef="c125" unitRef="usd"/>
  <us-gaap:StockholdersEquity id="f286" decimals="0" contextRef="c4" unitRef="usd">-23079.0</us-gaap:StockholdersEquity>
  <us-gaap:NetIncomeLoss id="f287" xsi:nil="true" contextRef="c114" unitRef="usd"/>
  <us-gaap:NetIncomeLoss id="f288" xsi:nil="true" contextRef="c129" unitRef="usd"/>
  <us-gaap:NetIncomeLoss id="f289" xsi:nil="true" contextRef="c130" unitRef="usd"/>
  <us-gaap:GeneralAndAdministrativeExpense id="f290" decimals="0" contextRef="c2" unitRef="usd">1665.0</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:StockholdersEquity id="f291" decimals="0" contextRef="c138" unitRef="usd">20000.0</us-gaap:StockholdersEquity>
  <us-gaap:AssetsCurrent id="f292" decimals="0" contextRef="c14" unitRef="usd">5778.0</us-gaap:AssetsCurrent>
  <us-gaap:NetIncomeLoss id="f293" xsi:nil="true" contextRef="c133" unitRef="usd"/>
  <us-gaap:AccountsPayableCurrent id="f294" decimals="0" contextRef="c4" unitRef="usd">143331.0</us-gaap:AccountsPayableCurrent>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f295" decimals="INF" contextRef="c4" unitRef="usd1">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <pointofcarenano.com:ShareSubscriptionReceived id="f296" xsi:nil="true" contextRef="c2" unitRef="usd"/>
  <us-gaap:StockholdersEquity id="f297" decimals="0" contextRef="c28" unitRef="usd">1.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f298" decimals="0" contextRef="c116" unitRef="usd">94.0</us-gaap:StockholdersEquity>
  <pointofcarenano.com:UnissuedCommonStocks id="f299" decimals="0" contextRef="c135" unitRef="usd">750000.0</pointofcarenano.com:UnissuedCommonStocks>
  <dei:AmendmentFlag id="f300" contextRef="c2">false</dei:AmendmentFlag>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="f301" decimals="INF" contextRef="c14" unitRef="usd1">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:StockholdersEquity id="f302" decimals="0" contextRef="c139" unitRef="usd">-120951880.0</us-gaap:StockholdersEquity>
  <us-gaap:StockRedeemedOrCalledDuringPeriodValue id="f303" decimals="0" contextRef="c135" unitRef="usd">4603.0</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
  <dei:CurrentFiscalYearEndDate id="f304" contextRef="c2">--07-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="f305" xsi:nil="true" contextRef="c2" unitRef="usd"/>
  <us-gaap:UseOfEstimates id="f306" contextRef="c2">&lt;p id="xdx_847_eus-gaap--UseOfEstimates_z73fYh6AvcCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zqiuOqQeiav1"&gt;Use
of Estimates&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent
assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period.
Changes in estimates are recognized in accordance with the accounting rules for the estimate, which is typically in the period when new
information becomes available to management. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
  <us-gaap:NetIncomeLoss id="f307" decimals="0" contextRef="c2" unitRef="usd">-6308.0</us-gaap:NetIncomeLoss>
  <us-gaap:StockholdersEquity id="f308" decimals="0" contextRef="c140" unitRef="usd">-120268417.0</us-gaap:StockholdersEquity>
  <us-gaap:IntangibleAssetsFiniteLivedPolicy id="f309" contextRef="c2">&lt;p id="xdx_848_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zD6Uyn5KX2K5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zUQCrBPWuD15"&gt;Intangible
assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
asset are non-monetary identifiable assets, controlled by the Company that will produce future economic benefits, based on reasonable
and supportable assumptions about conditions that will exist over the life of the asset. An intangible asset that does not meet these
attributes will be recognized as an expense when it is incurred. Intangible assets that do, are capitalized and initially measure at
cost. Those with a determinable life will be amortized on a systematic basis over their future economic life. Those with an indefinite
useful life shall not be amortized until its useful life is determined to be longer than indefinite. An intangible asset subject to amortization
shall be periodically reviewed for impairment. A recoverability test will be performed and, if applicable, unscheduled amortization is
considered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
license agreements has been capitalized, recorded at cost and amortized over its estimated useful life of &lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxH_c20231031_zsopxcxWooL1" title="::XDX::P10Y"&gt;ten&lt;/span&gt; years. Amortization has
been determined based on a pro rata basis over the expected cash flows.&lt;/span&gt;&lt;/p&gt;





</us-gaap:IntangibleAssetsFiniteLivedPolicy>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="f310" decimals="0" contextRef="c23" unitRef="usd">17822.0</us-gaap:IncreaseDecreaseInAccountsPayable>
  <dei:DocumentFiscalYearFocus id="f311" contextRef="c2">2024</dei:DocumentFiscalYearFocus>
  <us-gaap:InterestPaidNet id="f312" xsi:nil="true" contextRef="c2" unitRef="usd"/>
  <us-gaap:NetIncomeLoss id="f313" decimals="0" contextRef="c141" unitRef="usd">-13795.0</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding id="f314" decimals="INF" contextRef="c131" unitRef="shares">940621.0</us-gaap:SharesOutstanding>
  <us-gaap:NetIncomeLoss id="f315" decimals="0" contextRef="c21" unitRef="usd">-9773.0</us-gaap:NetIncomeLoss>
  <dei:DocumentFiscalPeriodFocus id="f316" contextRef="c2">Q1</dei:DocumentFiscalPeriodFocus>
  <us-gaap:InterestPaidNet id="f317" xsi:nil="true" contextRef="c23" unitRef="usd"/>
  <dei:DocumentQuarterlyReport id="f318" contextRef="c2">true</dei:DocumentQuarterlyReport>
  <us-gaap:OperatingIncomeLoss id="f319" decimals="0" contextRef="c2" unitRef="usd">-6308.0</us-gaap:OperatingIncomeLoss>
  <dei:EntityCentralIndexKey id="f320" contextRef="c2">0001504239</dei:EntityCentralIndexKey>
  <us-gaap:IncomeTaxesPaid id="f321" xsi:nil="true" contextRef="c2" unitRef="usd"/>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="f322" decimals="0" contextRef="c4" unitRef="usd">423.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity id="f323" decimals="0" contextRef="c14" unitRef="usd">-16771.0</us-gaap:StockholdersEquity>
  <pointofcarenano.com:ConsultingExpense id="f324" xsi:nil="true" contextRef="c2" unitRef="usd"/>
  <us-gaap:IncomeTaxesPaid id="f325" xsi:nil="true" contextRef="c23" unitRef="usd"/>
  <us-gaap:CommonStockValue id="f326" decimals="0" contextRef="c4" unitRef="usd">42.0</us-gaap:CommonStockValue>
  <pointofcarenano.com:ShareSubscriptionReceived id="f327" xsi:nil="true" contextRef="c142" unitRef="usd"/>
  <pointofcarenano.com:LicenseFeeToBePaidInCommonShares id="f328" xsi:nil="true" contextRef="c2" unitRef="usd"/>
  <us-gaap:QuarterlyFinancialInformationTextBlock id="f329" contextRef="c2">&lt;p id="xdx_809_eus-gaap--QuarterlyFinancialInformationTextBlock_zemFxM09o008" style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
    3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 91%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_828_zghn1lJSCxD4"&gt;INTERIM
    REPORTING&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;While
the information presented in the accompanying interim three month financial statements is unaudited, it includes all adjustments, which
are, in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the interim
periods presented in accordance with accounting principles generally accepted in the United States of America. These interim financial
statements follow the same accounting policies and methods of their application as the Companys July 31, 2023 annual financial
statements. All adjustments are of a normal recurring nature. It is suggested that these interim financial statements be read in conjunction
with the Companys July 31, 2023 annual financial statements. Operating results for the three months ended October 31, 2023 are
not necessarily indicative of the results that can be expected for the year ended July 31, 2024.&lt;/span&gt;&lt;/p&gt;

</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:StockholdersEquity id="f330" decimals="0" contextRef="c126" unitRef="usd">94.0</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="f331" decimals="0" contextRef="c143" unitRef="usd">-120942107.0</us-gaap:StockholdersEquity>
  <pointofcarenano.com:ShareSubscriptionReceived id="f332" xsi:nil="true" contextRef="c" unitRef="usd"/>
  <pointofcarenano.com:LicenseFeeToBePaidInCommonShares id="f333" xsi:nil="true" contextRef="c23" unitRef="usd"/>
  <us-gaap:PreferredStockSharesAuthorized id="f334" decimals="INF" contextRef="c4" unitRef="shares">10000000.0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:GeneralAndAdministrativeExpense id="f335" decimals="0" contextRef="c23" unitRef="usd">3722.0</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:StockholdersEquity id="f336" decimals="0" contextRef="c95" unitRef="usd">94.0</us-gaap:StockholdersEquity>
  <dei:CityAreaCode id="f337" contextRef="c2">(732)</dei:CityAreaCode>
  <pointofcarenano.com:ShareSubscriptionReceived id="f338" xsi:nil="true" contextRef="c3" unitRef="usd"/>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife id="f339" contextRef="c4">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:AccountsPayableCurrent id="f340" decimals="0" contextRef="c14" unitRef="usd">141414.0</us-gaap:AccountsPayableCurrent>
  <us-gaap:PreferredStockSharesAuthorized id="f341" decimals="INF" contextRef="c14" unitRef="shares">10000000.0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:StockholdersEquity id="f342" decimals="0" contextRef="c144" unitRef="usd">-86729.0</us-gaap:StockholdersEquity>
  <pointofcarenano.com:ShareSubscriptionReceived id="f343" xsi:nil="true" contextRef="c6" unitRef="usd"/>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="f344" contextRef="c2">&lt;p id="xdx_80F_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zIti1ffs7rV2" style="margin-top: 0; margin-bottom: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Note
    5&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 91%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_825_z51Vkv50RZO8"&gt;COMMON
    and PREFERRED STOCK&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has authorized capital of &lt;span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20231031_zkwGkufYHJBl"&gt;100,000,000&lt;/span&gt; shares of common stock, par value of $&lt;span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231031_zFl8c6Q8omLj"&gt;0.0001&lt;/span&gt; per share, and &lt;span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20231031_zF0acFGJfSoc"&gt;10,000,000&lt;/span&gt; shares of blank
check preferred stock, par value of $&lt;span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231031_zRCTlPTgGFi7"&gt;0.0001&lt;/span&gt; per share, of which none have been designated as Series A Nonconvertible Preferred
Stock (the Series A Preferred Stock). There were no transactions for the 3 months ended October 31, 2023. During the year
ended July 31, 2023, the Company had the following transactions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_eus-gaap--StockholdersEquityReverseStockSplit_c20220608__20220608_zg9GbDCjBp7b"&gt;On
June 8, 2022, the Company received approval from the Financial Industry Regulatory Authority to effect a 50:1 reverse split of our outstanding
common stock. The split was reflected in the public markets on June 9, 2022 and has been given retroactive disclosure in the financial
statements.&lt;/span&gt; Accordingly, all references to common shares in these financial statements reflect the reverse split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 2, 2021, the Company issued &lt;span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_c20210802_z5Fqkjm2tZTk"&gt;1,000&lt;/span&gt; Series A Preferred Stock to &lt;span id="xdx_915_esrt--ChiefExecutiveOfficerMember_zJZQR0GYw0ri"&gt;Nicholas DeVito&lt;/span&gt;, our Chief Executive Officer as compensation. The
Preferred Stock gives DeVito 80% control of the voting stock of the Company. Mr. DeVito surrendered his preferred shares in exchange
for 5,000,000 shares of Company common stock on May 21, 2024.   &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 10, 2022, the Company entered into an agreement under which it agreed to issue 300,000 common shares in order to obtain a license
to distribute product (See below). The Company has not yet issued those shares and the obligation to do so is recorded as a &lt;span id="xdx_90E_ecustom--LicenseFeeToBePaidInCommonShares_c20220410__20220410_zvNVAoXRK9id"&gt;$750,000&lt;/span&gt;
unissued stock in equity.      &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 15, 2022, as part of the Settlement agreement (See below), the Company received into treasury &lt;span id="xdx_905_ecustom--TreasuryStockShares1_iI_c20220415_zNCSzhsFEXx2"&gt;520,000&lt;/span&gt; shares of common stock (26,000,000
pre reverse split shares).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;  &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 24, 2022, the Company completed a financing with an investor for $20,000   in exchange for Units consisting of (i) one
share of common stock, par value $0.0001   per share for $0.10 per share, (ii) one LOI option to purchase one share of common
stock for $0.20 per share upon the Company signing a letter of intent with a third party and (iii) one Agreement option to purchase one
share of common stock for $0.30 per share upon the Company signing an agreement with a third party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no warrants or options outstanding as of October 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt; &lt;/span&gt;&lt;/p&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:NetIncomeLoss id="f345" decimals="0" contextRef="c145" unitRef="usd">-27019.0</us-gaap:NetIncomeLoss>
  <pointofcarenano.com:ShareSubscriptionReceived id="f346" xsi:nil="true" contextRef="c7" unitRef="usd"/>
  <us-gaap:NetIncomeLoss id="f347" decimals="0" contextRef="c146" unitRef="usd">-5837.0</us-gaap:NetIncomeLoss>
  <dei:LocalPhoneNumber id="f348" contextRef="c2">723-7395</dei:LocalPhoneNumber>
  <pointofcarenano.com:ShareSubscriptionReceived id="f349" xsi:nil="true" contextRef="c8" unitRef="usd"/>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="f350" decimals="0" contextRef="c4" unitRef="usd">115989.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:NetIncomeLoss id="f351" xsi:nil="true" contextRef="c142" unitRef="usd"/>
</xbrli:xbrl>
